[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mild-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mild-stroke":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100600307","phase-4-tirofiban-with-sequential-dual-antiplatelet-therapy-in-mild-stroke-100600307",false,"NCT07095790","Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke","Tirofiban With Sequential Dual Antiplatelet Therapy Versus Dual Antiplatelet Therapy Alone in Mild Acute Ischemic Stroke (TiMIS): A Multicenter, Open-Label, Blinded-Endpoint, Parallel-Controlled, Randomized Clinical Trial","TiMIS","Inclusion Criteria:\n\n1. Age: 18-80 years old.\n2. Acute mild non-cardioembolic stroke.\n3. NIHSS score ≤5.\n4. Time from onset to randomization of ≤48 hours; if the time of onset is unknown, time from the last known time of being well to randomization of ≤48 hours.\n5. The investigational drug can be administered within 48 hours of symptom onset.\n6. Signed informed consent by the patient or legally authorized representative.\n\nExclusion Criteria:\n\n1. Received or planned to receive intravenous thrombolysis or bridging therapy (with subsequent endovascular treatment)\n2. Intracranial hemorrhage confirmed by imaging.\n3. Pre-stroke modified Rankin Scale (mRS) score ≥2.\n4. Any confirmed cardioembolic source, including chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, infective endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction \\\u003C30%.\n5. History of primary intracerebral hemorrhage.\n6. History of other intracranial hemorrhage (intraventricular, subarachnoid, epidural, or subdural hemorrhage).\n7. Untreated or inadequately treated intracranial aneurysm or vascular malformation.\n8. Major systemic bleeding within 30 days.\n9. Active bleeding, including laboratory evidence of coagulopathy (platelet count \\\u003C100 × 10⁹\u002FL, activated partial thromboplastin time \\>50 seconds, or international normalized ratio \\>1.7), or treatment with direct oral anticoagulants within the preceding 48 hours.\n10. Major surgery within 14 days.\n11. Persistently elevated blood pressure (systolic \\>180 mmHg or diastolic \\>110 mmHg) despite treatment.\n12. Baseline platelet count \\\u003C100 × 10⁹\u002FL.\n13. Severe renal dysfunction (glomerular filtration rate \\\u003C30 mL\u002Fmin or serum creatinine \\>220 μmol\u002FL \\[2.5 mg\u002FdL\\]).\n14. Known allergy or contraindication to tirofiban or aspirin.\n15. Current pregnancy or lactation.\n16. Any intracranial tumor (except asymptomatic meningiomas ≤1.5 cm in diameter).\n17. Any terminal illness with life expectancy \\\u003C6 months.","ALL","18 Years","80 Years",{"count":21,"type":22},580,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This study aims to evaluate whether initiating intravenous tirofiban within 48 hours of onset (with a 48-hour infusion), followed by sequential DAPT, can improve the likelihood of excellent functional outcomes (modified Rankin Scale score 0-1) in mild stroke patients, compared with standard DAPT therapy based on current guidelines.",[28],"Mild Stroke",[30],"Tirofiban; Dual Antiplatelet Therapy; Mild Stroke","RECRUITING","2025-07-23",{"date":34,"type":35},"2025-07-31","ACTUAL",{"date":37,"type":22},"2025-08-30",{"date":39,"type":22},"2027-05-31",{"name":41,"class":42},"Second Affiliated Hospital of Soochow University","OTHER",18,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100551795","endovascular-treatment-for-mild-ischemic-stroke-due-to-acute-large-vessel-occlusion-in-the-anterior-circulation-100551795","NCT06464731","Endovascular Treatment for Mild Ischemic Stroke Due to Acute Large Vessel Occlusion in the Anterior Circulation","Endovascular Treatment for Mild Ischemic Stroke Due to Acute Large Vessel Occlusion in the Anterior Circulation: A Multicenter Prospective Registry","Mild-MT","Inclusion Criteria:\n\n1. Age 18-80 years old;\n2. Symptoms onset or last known well to randomization is within 24 hours.\n3. Clinical diagnosis of acute ischemic stroke due to anterior circulation intracranial large vessel occlusion (LVO) (including intracranial internal carotid artery \\[ICA\\], middle cerebral artery \\[MCA\\] M1 segment, MCA M2 segment, with or without ipsilateral extracranial ICA occlusion) confirmed on Computerized tomography angiography (CTA) or Magnetic resonance imaging angiography (MRA) ;\n4. Baseline NIHSS score \\\u003C6 before randomization (including cases with NIHSS ≥6 at onset but improves before randomization);\n5. ASPECTS score ≥6 based on Non-contrast CT (NCCT) before randomization;\n\nExclusion Criteria:\n\n1. Premorbid Rankin Scale (mRS) score ≥ 1;\n2. Known allergy to iodine, heparin, anaesthesia, or other definite contraindication to receiving endovascular treatment (EVT) procedure;\n3. Patient has severe or fatal co-morbidities that could interfere with outcome assessments and follow-up (such as malignant tumor, severe heart failure, or renal failure, or life expectancy less than 6 months);\n4. Poorly controlled hypertension (systolic blood pressure \\>220 mmHg or diastolic blood pressure \\>120 mmHg);\n5. Baseline blood glucose \\\u003C50mg\u002FdL (2.78 mmol\u002FL) or \\>400mg\u002FdL (22.20 mmol\u002FL);\n6. Known bleeding tendencies, including but not limited to platelet count \\\u003C100×109\u002FL; received heparin treatment within 48 hours with an activated partial thromboplastin time (APTT) ≥35s; recent oral anticoagulant therapy with international normalized ratio (INR) \\>3; Note: Patients without a history of coagulation abnormalities or without suspicion of coagulation abnormalities do not need to wait for laboratory test results before enrollment;\n7. Seizures at stroke onset or during the course, hard to accurately judge the baseline NIHSS score;\n8. Female who is known to be pregnant, lactation, or tested positive for pregnancy at time of admission;\n9. Currently participating in another investigational drug study or medical device treatments that may interfere with the results of this study;\n10. Evidence of intracranial hemorrhage on CT\u002FMRI, including cerebral parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, and subdural\u002Fextradural hemorrhage;\n11. Significant midline displacement, hernia of brain, or ventricular mass effect with midline displacement confirmed on CT\u002FMRI;\n12. Anticipated impossibility to complete endovascular treatment, such as vascular tortuosity, severe vascular wall calcification, etc.;\n13. Aortic dissection;\n14. Multiple intracranial large vessel occlusions confirmed by CTA or MRA, unable to clearly identify the symptomatic vessel, such as bilateral MCA occlusions or occlusions involving both the MCA and basilar artery;\n15. Suspected or confirmed occluded artery is non-acute occlusion.",{"count":53,"type":22},200,[55],"NA","Explore the effectiveness and safety of emergency endovascular treatment in patients with mild ischemic stroke due to acute large vessel occlusion in the anterior circulation, identified through perfusion imaging.",[58,28],"Endovascular Treatment",[60,61],"endovascular treatment","mild stroke","2024-06-12",{"date":64,"type":35},"2024-06-18",{"date":66,"type":35},"2017-01-01",{"date":68,"type":22},"2024-12-30",{"name":70,"class":42},"Wen-huo Chen",9]